Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.78 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022840 | 0.91 | GRM2 (0.75) | GRM2GRIN2BPPARGPPARDPPARA | |
| SCHEMBL2025577 | 0.91 | GRM2 (0.75) | GRM2GRIN2BPPARGPPARDPPARA | |
| SCHEMBL1003316 | 0.89 | GRM2 (0.85) | GRM2PPARGPPARDPPARASCN5A | |
| SCHEMBL2024656 | 0.89 | GRM2 (0.73) | GRM2GRIN2BPPARGPPARDPPARA | |
| SCHEMBL2023554 | 0.89 | GRM2 (0.84) | GRM2PPARGPPARDPPARASCN5A | |
| SCHEMBL2124540 | 0.88 | GRM2 (1.00) | GRM2GRIN2BPPARGPPARDPPARA | |
| SCHEMBL1000992 | 0.87 | GRM2 (0.81) | GRM2GRIN2BPPARGPPARDPPARA | |
| SCHEMBL2125177 | 0.86 | GRM2 (0.59) | GRM2ALDH1A1KCNH2MAPK1L3MBTL1 | |
| SCHEMBL3670292 | 0.85 | GRM2 (0.57) | GRM2ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL3090130 | 0.84 | GRM2 (0.62) | GRM2GRIN2BTYMSSCN5AS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2444399-B1 | Oxadiazole derivatives and their use as metabotropic glutamate receptor -842 potentiators | ASTRAZENECA AB (SE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2167502-B3 | OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842 | ASTRAZENECA AB (SE) | 2013-07-10 | — | — | EP | disclosed |
| US-8377939-B2 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842 | ASTRAZENECA AB (SE) | 2013-02-19 | — | — | US | disclosed |
| US-8377940-B2 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators—842 | ASTRAZENECA AB (SE) | 2013-02-19 | — | — | US | disclosed |
| EP-2167502-B1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842 | ASTRAZENECA AB (SE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2444399-A1 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842 | AstraZeneca AB (SE) | 2012-04-25 | — | — | EP | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20100267740-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators - 842 | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | US | disclosed |
| EP-2167502-A1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842 | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20080306077-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008150233-A1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306077-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 | GRM1, GRIN1, GRM2 | GRM2 3/4885GRIN2B 7/4885PPARG 461/4885 |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | GRM2 4/4885GRIN2B 16/4885PPARG 645/4885 |
| US-20100267740-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators - 842 | GRM1, GRM2, GRIN1 | GRM2 2/4885GRIN2B 9/4885PPARG 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.